Medication info
Neurocabapine Capsule 300 mg (Pregabalin)

Neurocabapine Capsule 300 mg (Pregabalin)

Prescription medicationHard capsule
Ingredient · strength
Pregabalin›300mg / 1 capsule
Manufacturer / importer
Samjin Pharmaceutical Co., Ltd.
Appearance
A hard capsule with a reddish-brown upper part and white lower part containing a white to pale yellow powder.
Packaging
30C/bottle
Approval status
Active

MFDS item code 201708174 · Approved 2017.11.30 · Insurance code 647804600

Summary

Main use
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial-onset seizures
Who uses it
Adults · Children
Adult dosage
This medication is administered orally as pregabalin, in 2 divided doses per day, with or without food. Since this medication is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medication may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, the dose may subsequently be increased at 7-day intervals up to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: This medication may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation’) 2. Epilepsy Adults: This medication may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 1 week. If necessary, the dose may subsequently be increased at 7-day intervals up to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medication for fibromyalgia is 300 mg ~ 450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies were also conducted at a dose of 600 mg/day; however, there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation Based on current clinical experience, if this medication is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with renal impairment After entering the systemic circulation, this medication is primarily excreted by the kidneys unchanged. Since the clearance of this medication is directly affected by creatinine clearance, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the formula below. Creatinine clearance (ml/min)* = DRW00001f484135 * For women, multiply the result obtained using the above equation by 0.85. This medication is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered immediately after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosage based on renal function Creatinine clearance (CLcr), (mL/min) / Total daily dose of pregabalin a / Administration method / Starting dose (mg/day) / Maximum dose (mg/day) ≥60 / 150 / 600 / BID or TID ≥30 -<60 / 75 / 300 / BID or TID ≥15 -<30 / 25-50 / 150 / QD or BID <15 / 25 / 75 / QD Supplemental dose after hemodialysis / 25 / 100 / Single dose b TID = Total daily dose divided into 3 doses BID = Total daily dose divided into 2 doses QD = Once daily a The total daily dose (mg/day) should be divided as indicated under administration method. b Supplemental dose refers to an additional dose administered as a single dose. 6. Patients with hepatic impairment Dose adjustment is not necessary in patients with hepatic impairment. 8. Older adults (65 years of age and older) Dose reduction may be necessary in older adults with impaired renal function.
Children's dosage
There are insufficient safety and efficacy data for children under 12 years of age and adolescents aged 12–17 years; therefore, use is not recommended.

Ingredients

Manufacturer
Samjin Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial-onset seizures

  • Peripheral neuropathic pain
  • central neuropathic pain
  • epilepsy
  • secondary general symptoms
  • partial seizures
  • fibromyalgia
View approved original text

This medication is used to relieve peripheral and central neuropathic pain in adults. It is also utilized as an adjunct treatment for partial seizures in patients with epilepsy, with or without secondary general symptoms. Furthermore, it is effective in relieving symptoms in patients with fibromyalgia, aiding overall pain management. It is used to treat a variety of neurological pain and epilepsy symptoms.

Dosage and Administration

Adult dosage

This medication is administered orally as pregabalin, in 2 divided doses per day, with or without food. Since this medication is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medication may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, the dose may subsequently be increased at 7-day intervals up to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: This medication may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation’) 2. Epilepsy Adults: This medication may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 1 week. If necessary, the dose may subsequently be increased at 7-day intervals up to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medication for fibromyalgia is 300 mg ~ 450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies were also conducted at a dose of 600 mg/day; however, there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation Based on current clinical experience, if this medication is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with renal impairment After entering the systemic circulation, this medication is primarily excreted by the kidneys unchanged. Since the clearance of this medication is directly affected by creatinine clearance, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the formula below. Creatinine clearance (ml/min)* = DRW00001f484135 * For women, multiply the result obtained using the above equation by 0.85. This medication is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered immediately after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosage based on renal function Creatinine clearance (CLcr), (mL/min) / Total daily dose of pregabalin a / Administration method / Starting dose (mg/day) / Maximum dose (mg/day) ≥60 / 150 / 600 / BID or TID ≥30 -<60 / 75 / 300 / BID or TID ≥15 -<30 / 25-50 / 150 / QD or BID <15 / 25 / 75 / QD Supplemental dose after hemodialysis / 25 / 100 / Single dose b TID = Total daily dose divided into 3 doses BID = Total daily dose divided into 2 doses QD = Once daily a The total daily dose (mg/day) should be divided as indicated under administration method. b Supplemental dose refers to an additional dose administered as a single dose. 6. Patients with hepatic impairment Dose adjustment is not necessary in patients with hepatic impairment. 8. Older adults (65 years of age and older) Dose reduction may be necessary in older adults with impaired renal function.

Children's dosage

There are insufficient safety and efficacy data for children under 12 years of age and adolescents aged 12–17 years; therefore, use is not recommended.

Precautions

This medication may increase the risk of suicidal thoughts or behaviors, so patients should immediately inform healthcare professionals if they experience mood changes or depressive symptoms while taking it. It should not be taken if there is an allergy to any component in this drug. Patients with diabetes may experience weight gain during treatment, which may require adjustments to their blood sugar control medications. If symptoms such as swelling of the face, neck, or around the mouth, or difficulty breathing occur, patients should immediately stop taking the medication and consult a healthcare professional. Elderly patients should be cautious as dizziness or drowsiness may increase, raising the risk of falls or injuries. This medication may cause blurred vision or changes in vision; patients should inform healthcare professionals if these symptoms occur. Abruptly discontinuing this medication may lead to withdrawal symptoms such as insomnia, headache, and anxiety, so it should be tapered off gradually under the guidance of a healthcare professional. There is a risk of drug abuse; patients with a history of substance abuse should exercise particular caution, and any abnormal behaviors during use should be reported immediately. Patients with impaired kidney function may need a dosage adjustment for this medication. Patients with heart conditions should take this medication with caution, and if symptoms of heart failure occur, they should consult a healthcare professional. Taking this drug with other medications that have central nervous system depressant effects may increase the risk of drowsiness or respiratory depression, so caution is warranted. Pregnant women are advised not to take this medication in the early stages of pregnancy due to potential effects on the fetus, and fertile women should use effective contraceptive methods. Breastfeeding women should consider discontinuing breastfeeding or stopping the medication, as it may pass into breast milk. Activities requiring alertness, such as driving or operating machinery, should be avoided until dizziness or drowsiness from this medication resolves. If severe skin rashes, swelling, or breathing difficulties occur, patients should immediately stop the medication and inform their healthcare professional. In case of overdose, symptoms such as confusion, drowsiness, depression, or seizures may occur, necessitating immediate emergency treatment, and blood dialysis may be performed if needed. This medication should be kept out of reach of children, and transferring it to other containers is discouraged.

Side effects

Suicidal ideation, suicidal behavior, depression, abnormal changes in mood and behavior, angioedema, facial swelling, swelling around the mouth, upper respiratory tract swelling, dizziness, drowsiness, loss of consciousness, confusion, mental disorders, blurred vision, changes in vision, insomnia, headache, nausea, anxiety, diarrhea, influenza-like symptoms, restlessness, depression, suicidal thoughts, pain, seizures, sweating, misuse, abuse, dependence, congestive heart failure, severe respiratory depression, reduced respiratory function, respiratory diseases, neurological disorders, kidney disorders, rhinitis, neutropenia, increased appetite, decreased appetite, hypoglycemia, confusion, orientation disturbance, irritability, elation, decreased libido, depersonalization, dysesthesia, agitation, mood fluctuations, emotional distress, emotional elevation, hallucinations, abnormal dreams, increased libido, panic attacks, lack of impulse control, apathy, ataxia, coordination disorders, balance disorders, amnesia, attention disorders, memory disorders, tremors, speech disorders, sensory disturbances, sensory decrease, sedation, drowsiness, cognitive impairment, nystagmus, language disorders, clonic spasm, reflex decrease, movement disorders, psychomotor agitation, positional dizziness, hypersensitivity, burning sensation, activity tremors, syncope, confusion, decreased motility, olfactory disturbances, taste loss, writing difficulties, blurred vision, diplopia, indirect vision loss, visual disturbances, visual field defects, photophobia, dry eyes, ocular swelling, decreased vision, eye pain, eye fatigue, increased tear secretion, ocular irritation, mydriasis, changes in depth perception during vibration, strabismus, visual brightness, vertigo, auditory hypersensitivity, first-degree AV block, tachycardia, sinus bradycardia, sinus tachycardia, sinus arrhythmia, hypotension, hypertension, flushing, facial flushing, peripheral coldness, dyspnea, epistaxis, cough, nasal congestion, rhinitis, snoring, pharyngeal tension, nasal dryness, respiratory depression, vomiting, abdominal distension, constipation, dry mouth, bloating, excessive salivation, gastroesophageal reflux disease, oral sensory decrease, ascites, dysphagia, pancreatitis, sweating, papular rash, urticaria, cold sweat, muscle cramps, arthralgia, dorsalgia, limb pain, cervical spasm, joint swelling, myalgia, muscle spasm, neck pain, muscle stiffness, rhabdomyolysis, urination disorders, urinary incontinence, decreased urination, renal failure, erectile dysfunction, delayed ejaculation, sexual dysfunction, dysmenorrhea, amenorrhea, mastalgia, nipple discharge, gynecomastia, peripheral edema, edema, gait abnormalities, falls, feeling intoxicated, altered sensations, fatigue, chest tightness, generalized edema, pain, fever, chills, weakness, thirst, weight gain, increased alanine aminotransferase, increased serum creatine phosphokinase, increased aspartate aminotransferase, increased blood sugar, decreased platelet count, decreased serum potassium, weight loss, increased serum creatinine, decreased white blood cell count, hypersensitivity, allergic reactions, headache, keratitis, pulmonary edema, nausea, diarrhea, tongue swelling, itching, Stevens-Johnson syndrome, toxic epidermal necrolysis, urinary retention, gynecomastia, lethargy, delirium, paralysis, affective disorders, drowsiness, confusion state, agitation, restlessness, exacerbation of seizures, sleep disorders, gastrointestinal disturbances, tinnitus, increased BUN, urination difficulties

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to protect it from air and moisture, and it is safest to store it at room temperature between 1°C and 30°C. Proper storage maintains the drug's effectiveness and prevents deterioration.

Appearance and packaging

Appearance

A hard capsule with a reddish-brown upper part and white lower part containing a white to pale yellow powder.

Package unit

30C/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.